scholarly article | Q13442814 |
P50 | author | Maria Morello | Q61134075 |
Vincenza D'Angelo | Q38323218 | ||
Alessandro Martorana | Q45299885 | ||
P2093 | author name string | Giorgio Bernardi | |
Giuseppe Sancesario | |||
Carmela Giampà | |||
Francesca R Fusco | |||
Zena DeMarch | |||
P2860 | cites work | Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum | Q34090320 |
Transcriptional abnormalities in Huntington disease | Q35113363 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Huntington's disease | Q190564 |
excitotoxicity | Q901117 | ||
striatum | Q1319792 | ||
P304 | page(s) | 11-20 | |
P577 | publication date | 2006-01-01 | |
P1433 | published in | European Journal of Neuroscience | Q5412733 |
P1476 | title | Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease | |
P478 | volume | 23 |
Q37345118 | A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease |
Q37061555 | BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. |
Q37139004 | Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia |
Q48093702 | Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry |
Q52676144 | Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease. |
Q28748849 | Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease |
Q38085375 | Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. |
Q37750542 | Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease |
Q92269192 | Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease |
Q90439419 | Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences |
Q28547107 | PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease |
Q47732711 | Role of Phosphodiesterases in Huntington's Disease |
Q38616832 | Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease |
Q34017941 | Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice |
Q28488296 | Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease |
Q21092845 | The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease |
Q41821958 | Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease |
Search more.